Market Closed -
Nasdaq
04:00:00 2024-05-23 pm EDT
|
5-day change
|
1st Jan Change
|
31.73
USD
|
-4.28%
|
|
+1.15%
|
-2.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
774.7
|
806.6
|
1,178
|
909.5
|
759.2
|
789.9
|
-
|
-
|
Enterprise Value (EV)
1 |
774.7
|
806.6
|
1,178
|
909.5
|
759.2
|
789.9
|
789.9
|
789.9
|
P/E ratio
|
-50
x
|
-22.7
x
|
-71.3
x
|
662
x
|
-35.3
x
|
-26.7
x
|
-29.5
x
|
-39.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.7
x
|
11.3
x
|
12
x
|
7.44
x
|
5.1
x
|
3.93
x
|
3.33
x
|
2.79
x
|
EV / Revenue
|
10.7
x
|
11.3
x
|
12
x
|
7.44
x
|
5.1
x
|
3.93
x
|
3.33
x
|
2.79
x
|
EV / EBITDA
|
-727
x
|
-137
x
|
-6,472
x
|
4,007
x
|
151
x
|
92
x
|
42.9
x
|
25.4
x
|
EV / FCF
|
-26,186,586
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
16,487
|
19,555
|
19,678
|
22,892
|
23,353
|
23,829
|
-
|
-
|
Reference price
2 |
46.99
|
41.25
|
59.86
|
39.73
|
32.51
|
33.15
|
33.15
|
33.15
|
Announcement Date
|
3/4/20
|
3/10/21
|
3/2/22
|
2/28/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
72.55
|
71.08
|
98.05
|
122.3
|
148.7
|
201.1
|
237.2
|
283.4
|
EBITDA
1 |
-1.066
|
-5.871
|
-0.182
|
0.227
|
5.04
|
8.582
|
18.4
|
31.08
|
EBIT
1 |
-9.077
|
-26.76
|
-18.02
|
-25.4
|
-26.75
|
-26.68
|
-21.49
|
-12.95
|
Operating Margin
|
-12.51%
|
-37.64%
|
-18.38%
|
-20.77%
|
-17.99%
|
-13.27%
|
-9.06%
|
-4.57%
|
Earnings before Tax (EBT)
1 |
-12.68
|
-33.67
|
-17.39
|
-3.689
|
-21.31
|
-29.56
|
-27.07
|
-18.78
|
Net income
1 |
-13.73
|
-32.94
|
-16.26
|
1.258
|
-20.97
|
-27.22
|
-26.27
|
-19.44
|
Net margin
|
-18.93%
|
-46.35%
|
-16.58%
|
1.03%
|
-14.1%
|
-13.54%
|
-11.07%
|
-6.86%
|
EPS
2 |
-0.9400
|
-1.820
|
-0.8400
|
0.0600
|
-0.9200
|
-1.243
|
-1.125
|
-0.8400
|
Free Cash Flow
|
-29.58
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-40.78%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/10/21
|
3/2/22
|
2/28/23
|
3/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
24.81
|
23.42
|
32.93
|
34.95
|
30.99
|
31.59
|
39.56
|
39.97
|
37.61
|
44.68
|
52.48
|
53.8
|
50.59
|
51.86
|
62.02
|
EBITDA
1 |
-0.567
|
-1.594
|
2.103
|
1.903
|
-2.236
|
-2.053
|
2.272
|
3.598
|
1.295
|
-1.108
|
3.289
|
4.408
|
1.99
|
0.754
|
6.751
|
EBIT
1 |
-5.561
|
-6.386
|
-3.743
|
-3.352
|
-8.309
|
-8.591
|
-5.586
|
-4.508
|
-8.066
|
-9.723
|
-5.631
|
-4.292
|
-7.011
|
-7.601
|
-2.931
|
Operating Margin
|
-22.41%
|
-27.27%
|
-11.37%
|
-9.59%
|
-26.81%
|
-27.2%
|
-14.12%
|
-11.28%
|
-21.44%
|
-21.76%
|
-10.73%
|
-7.98%
|
-13.86%
|
-14.66%
|
-4.73%
|
Earnings before Tax (EBT)
1 |
-0.166
|
-9.417
|
-0.772
|
14.4
|
-7.897
|
-7.38
|
-3.287
|
-3.742
|
-6.903
|
-10.34
|
-6.677
|
-5.321
|
-8.057
|
-9.285
|
-4.614
|
Net income
1 |
0.072
|
-9.1
|
-0.333
|
18.54
|
-7.849
|
-6.806
|
-2.886
|
-4.591
|
-6.691
|
-7.805
|
-6.345
|
-5.12
|
-7.946
|
-9.179
|
-3.996
|
Net margin
|
0.29%
|
-38.86%
|
-1.01%
|
53.04%
|
-25.32%
|
-21.55%
|
-7.3%
|
-11.49%
|
-17.79%
|
-17.47%
|
-12.09%
|
-9.52%
|
-15.71%
|
-17.7%
|
-6.44%
|
EPS
2 |
-
|
-0.4700
|
-0.0200
|
0.8700
|
-0.3500
|
-0.3000
|
-0.1300
|
-0.2000
|
-0.2900
|
-0.3400
|
-0.2800
|
-0.2286
|
-0.3514
|
-0.3860
|
-0.1840
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/22
|
5/4/22
|
8/3/22
|
10/31/22
|
2/28/23
|
5/1/23
|
7/31/23
|
11/6/23
|
3/6/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-29.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
11.8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
16.29%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/10/21
|
3/2/22
|
2/28/23
|
3/6/24
|
-
|
-
|
-
|
Last Close Price
31.73
USD Average target price
43
USD Spread / Average Target +35.52% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.40% | 790M | | +10.24% | 128B | | -8.89% | 11.26B | | +3.31% | 9.28B | | +35.16% | 5.42B | | -23.90% | 4.8B | | +8.20% | 3.45B | | -10.69% | 2.8B | | -12.15% | 2.1B | | -11.96% | 1.98B |
Medical Devices & Implants
|